Effects of Lipopolysaccharide on the Induction of Mixed Chimerism in Cyclophosphamide-Induced Tolerance

Scandinavian Journal of Immunology

Volumn 70, Issue 5, 2009, Pages 423-430

  Onzuka, T ^a   Tomita, Y ^a   Shimizu, I ^a   Okano, S ^a   Yamada, H ^b   Yoshikai, Y ^b   Tominaga, R ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHIMERA; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TOLERANCE; FLOW CYTOMETRY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN GRAFT; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; CHIMERISM; CYCLOPHOSPHAMIDE; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; SKIN TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE;

EID: 70350505963     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2009.02314.x     Document Type: Article

References (59)

1. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001 14 : 417 424.
2. Kawai T, Cosimi AB, Spitzer TR et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008 358 : 353 361.
3. Tomita Y, Yoshikawa M, Zhang QW et al. Induction of permanent mixed chimerism and skin allograft tolerance across fully MHC-mismatched barriers by the additional myelosuppressive treatments in mice primed with allogeneic spleen cells followed by cyclophosphamide. J Immunol 2000 165 : 34 41.
4. Zhang QW, Tomita Y, Matsuzaki G et al. Heart allograft tolerance without development of posttransplant cardiac allograft vasculopathy in chimerism-based, drug-induced tolerance. Transplantation 2002 73 : 652 656.
5. Eto M, Mayumi H, Tomita Y, Yoshikai Y, Nishimura Y, Nomoto K. Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion. J Immunol 1990 145 : 1303 1310. (Pubitemid 20255030)
6. Tomita Y, Nishimura Y, Harada N et al. Evidence for involvement of clonal anergy in MHC class I and class II disparate skin allograft tolerance after the termination of intrathymic clonal deletion. J Immunol 1990 145 : 4026 4036.
7. Tomita Y, Mayumi H, Eto M, Nomoto K. Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance?. J Immunol 1990 144 : 463 473.
8. + T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens. J Exp Med 1990 171 : 97 113.
9. Mayumi H, Himeno K, Shin T, Nomoto K. Drug-induced tolerance to allografts in mice. IV. Mechanisms and kinetics of cyclophosphamide-induced tolerance. Transplantation 1985 39 : 209 215. (Pubitemid 15158481)
10. Shin T, Mayumi H, Himeno K, Sanui H, Nomoto K. Drug-induced tolerance to allografts in mice. I. Difference between tumor and skin grafts. Transplantation 1984 37 : 580 584.
11. Tomita Y, Ayukawa K, Yoshikai Y, Nomoto K. Mechanisms of cyclophosphamide-induced tolerance to IE-encoded alloantigens - evidence of clonal deletion in MHC antigen-reactive cells for skin allograft rejection. Transplantation 1992 53 : 602 612.
12. Maeda T, Eto M, Nishimura Y, Nomoto K, Kong YY. Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming. Immunology 1993 78 : 113 121.
13. Eto M, Mayumi H, Tomita Y, Yoshikai Y, Nishimura Y, Nomoto K. The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance. Eur J Immunol 1990 20 : 2005 2013. (Pubitemid 20355623)
14. Tomita Y, Khan A, Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol 1994 153 : 1087 1098.
15. Iwai T, Tomita Y, Zhang QW, Shimizu I, Nomoto K, Yasui H. Requirement of a higher degree of chimerism for skin allograft tolerance in cyclophosphamide-induced tolerance. Transpl Int 2005 17 : 795 803.
16. Zhang QW, Tomita Y, Matsuzaki G et al. Mixed chimerism, heart, and skin allograft tolerance in cyclophosphamide-induced tolerance. Transplantation 2000 70 : 906 916.
17. Iwai T, Tomita Y, Okano S et al. Regulatory roles of NKT cells in the induction and maintenance of cyclophosphamide-induced tolerance. J Immunol 2006 177 : 8400 8409.
18. Iwai T, Tomita Y, Shimizu I et al. The immunoregulatory roles of natural killer T cells in cyclophosphamide-induced tolerance. Transplantation 2007 84 : 1686 1695.
19. Onzuka T, Tomita Y, Shimizu I et al. Role of the cytokine profiles produced by invariant natural killer T cells in the initial phase of cyclophosphamide-induced tolerance. Transplantation 2008 86 : 1301 1310.
20. Chen L, Wang T, Zhou P et al. TLR engagement prevents transplantation tolerance. Am J Transplant 2006 6 : 2282 2291.
21. Reinke P, Fietze E, Ode-Hakim S et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994 344 : 1737 1738.
22. Valujskikh A, Pantenburg B, Heeger PS. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant 2002 2 : 501 509.
23. + T-cell-mediated, virus-induced autoimmune disease. J Biol Chem 2001 276 : 19396 19403.
24. Welsh RM, McNally JM, Brehm MA, Selin LK. Consequences of cross-reactive and bystander CTL responses during viral infections. Virology 2000 270 : 4 8.
25. Welsh RM, Markees TG, Woda BA et al. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J Virol 2000 74 : 2210 2218.
26. Williams MA, Tan JT, Adams AB et al. Characterization of virus-mediated inhibition of mixed chimerism and allospecific tolerance. J Immunol 2001 167 : 4987 4995.
27. Williams MA, Onami TM, Adams AB et al. Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J Immunol 2002 169 : 5387 5391.
28. Turgeon NA, Iwakoshi NN, Meyers WC et al. Virus infection abrogates CD8(+) T-cell deletion induced by donor-specific transfusion and anti-CD154 monoclonal antibody. Curr Surg 2000 57 : 505 506.
29. Brehm MA, Markees TG, Daniels KA, Greiner DL, Rossini AA, Welsh RM. Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections. J Immunol 2003 170 : 4077 4086.
30. Forman D, Welsh RM, Markees TG et al. Viral abrogation of stem cell transplantation tolerance causes graft rejection and host death by different mechanisms. J Immunol 2002 168 : 6047 6056.
31. Thornley TB, Brehm MA, Markees TG et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol 2006 176 : 1561 1570.
32. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003 111 : 1571 1578.
33. + T regulatory cell induction and function in transplant recipients after CD154 blockade is TLR4 independent. J Immunol 2006 176 : 5988 5994.
34. + T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol 2000 164 : 512 521.
35. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent toll-like receptor signals are required for reversal of regulatory T-cell-mediated CD8 tolerance. Nat Immunol 2004 5 : 508 515.
36. Wang T, Chen L, Ahmed E et al. Prevention of allograft tolerance by bacterial infection with Listeria monocytogenes. J Immunol 2008 180 : 5991 5999.
37. Imagawa DK, Millis JM, Olthoff KM et al. The role of tumor necrosis factor in allograft rejection. I. Evidence that elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation. Transplantation 1990 50 : 219 225.
38. Brehm MA, Mangada J, Markees TG et al. Rapid quantification of naive alloreactive T cells by TNF-alpha production and correlation with allograft rejection in mice. Blood 2007 109 : 819 826.
39. Gerber DA, Oettinger CW, D'Souza M, Milton GV, Larsen CP, Pearson TC. Prolongation of murine cardiac allograft survival by microspheres containing TNF alpha and IL1-beta neutralizing antibodies. J Drug Target 1995 3 : 311 315.
40. Wang Q, Liu Y, Wang J et al. Induction of allospecific tolerance by immature dendritic cells genetically modified to express soluble TNF receptor. J Immunol 2006 177 : 2175 2185.
41. Alheim K, Chai Z, Fantuzzi G et al. Hyperresponsive febrile reactions to interleukin (IL) 1alpha and IL-1beta, and altered brain cytokine mRNA and serum cytokine levels, in IL-1beta-deficient mice. Proc Natl Acad Sci USA 1997 94 : 2681 2686.
42. Kaplan AP, Ghebrehiwet B, Silverberg M, Sealey JE. The intrinsic coagulation-kinin pathway, complement cascades, plasma renin-angiotensin system, and their interrelationships. Crit Rev Immunol 1981 3 : 75 93.
43. Jansen PM, Pixley RA, Brouwer M et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996 87 : 2337 2344.
44. Li S, Boackle SA, Holers VM, Lambris JD, Blatteis CM. Complement component c5a is integral to the febrile response of mice to lipopolysaccharide. Neuroimmunomodulation 2005 12 : 67 80.
45. Medvedev AE, Flo T, Ingalls RR et al. Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-kappaB activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls. J Immunol 1998 160 : 4535 4542.
46. Steinman RM, Hawiger D, Liu K et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 2003 987 : 15 25.
47. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003 21 : 685 711.
48. Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004 20 : 539 550.
49. Cumberbatch M, Dearman RJ, Kimber I. Langerhans cells require signals from both tumour necrosis factor-alpha and interleukin-1 beta for migration. Immunology 1997 92 : 388 395. (Pubitemid 27488152)
50. Trevejo JM, Marino MW, Philpott N et al. TNF-alpha -dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc Natl Acad Sci USA 2001 98 : 12162 12167.
51. + T-cell-mediated suppression by dendritic cells. Science 2003 299 : 1033 1036.
52. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000 165 : 618 622.
53. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006 6 : 813 822.
54. + T-cell response. J Immunol 2007 178 : 5429 5433.
55. Brint EK, Xu D, Liu H et al. ST2 is an inhibitor of interleukin 1 receptor and toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004 5 : 373 379.
56. Didierlaurent A, Goulding J, Patel S et al. Sustained desensitization to bacterial toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008 205 : 323 329.
57. Sato S, Nomura F, Kawai T et al. Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol 2000 165 : 7096 7101.
58. Fisher CJ Jr., Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996 334 : 1697 1702.
59. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997 25 : 1095 1100.